GENERAL CHARACTERISTICS
Antimycotics for systemic use. Triazole derivatives. ATC Code J02А С01.
Indications to Use:
Treatment of such diseases in adults as:
– cryptococcal meningitis;
– coccidioidomycosis;
– invasive candidiasis;
– candidiasis of the mucous membranes, including candidiasis of the oropharynx and candidiasis of the esophagus candidum, chronic candidiasis of the skin and mucous membranes;
– chronic atrophic candidiasis (candidiasis caused by the use of dentures) with inefficiency of local dental hygiene means;
– vaginal candidiasis, acute or recurrent, when local therapy is inappropriate;
– Balanitis Candida, when local therapy is inappropriate;
– dermatomycosis, including mycosis of feet, mycosis of smooth skin, inguinal dermatomycosis; multicolored lichen and candidal skin infections, when systemic therapy is inappropriate;
– dermatophytic onychomycosis, when the use of other medicines is inappropriate.
Prevention of such diseases in adults as:
– relapse of cryptococcal meningitis in patients with a high risk of its development;
– relapse of candidiasis of the oropharynx or esophagus in HIV-infected patients with a high risk of its development;
– decrease in the frequency of recurrences of vaginal candidiasis (4 or more cases per year);
– prophylaxis of candidiasis infections in patients with prolonged neutropenia (for example, patients with malignant blood diseases who receive chemotherapy or patients in the transplantation of hematopoietic stem cells).
Children. The drug can be used in the form of capsules in this category of patients, when children are able to safely swallow the capsule, usually at the age of 5 years.
The drug is used in children for the treatment of candidiasis of the mucous membranes (candidiasis of the oropharynx, candidosis of the esophagus), invasive candidiasis, cryptococcal meningitis and for the prevention of candidal infections in patients with reduced immunity. The drug can be used as maintenance therapy to prevent the recurrence of cryptococcal meningitis in children at high risk of its development.
Therapy can begin before the results of culture and other laboratory studies; after receiving the results, antibiotic therapy should be adjusted accordingly.
First Aid
-
$11 -
GENERAL CHARACTERISTICS Psychostimulants and nootropics. ATC Code N06B Х Indications to Use: • Chronic and latent insufficiency of cerebral circulation in atherosclerosis and arterial hypertension; angiodistonic ischemic stroke of the brain and the condition after a stroke of the brain. • Post-traumatic encephalasthenia. • Encephalopathy of various origins. • Psycho-organic syndrome with a predominance of memory impairment and other cognitive functions or disturbances in the emotional-volitional sphere. • labyrinthopathy – dizziness, tinnitus, nausea, vomiting, nystagmus. • Ménière syndrome. • Prevention of kinetosis.$22 -
DOSAGE FORM Cream. Main physical and chemical properties : white opaque cream. COMPOUND active ingredient : 1 g of cream contains azelaic acid in terms of 100% dry matter 200 mg; Excipients : benzoic acid (E 210), glycerol monostearate 40-55, macrogol stearate, "CUTINA CBS", octyldodecanol, propylene glycol, glycerin, purified water. PHARMACOTHERAPEUTIC GROUP Topical acne treatments. ATX code D10A X03. INDICATIONS Treatment of acne (common acne), characterized by the presence of comedones, papules, pustules and small nodules.$45 -
Dosage form Syrup. Active ingredient 5 ml of syrup contains althea root dry extract (extractant water) in terms of 20,0% content of polysaccharides – 7.5 mg. Indications Cough in acute and chronic respiratory diseases: bronchitis, laryngitis, tracheitis, bronchial asthma, whooping cough.$18 -
DOSAGE FORM Chewable tablets. Main physicochemical properties : tablets of grayish-brown color with inclusions, round shape, with a flat surface, a score and a bevel. COMPOSITION active ingredient: 1 tablet contains marshmallow herb (Althaea officinalis L.) dry extract 1:40 (extractant - drinking water) - 100 mg; excipients: light magnesium carbonate, aspartame (E 951), tartaric acid, povidone, sucrose (sucrose), calcium stearate, colloidal anhydrous silicon dioxide, flavoring (orange). PHARMACOTHERAPEUTIC GROUP Expectorants. ATX code R05C A05. INDICATIONS FOR USE Cough in acute and chronic respiratory diseases accompanied by the formation of thick and viscous bronchial secretions and/or impaired expectoration: bronchitis, pneumonia, bronchiectasis, bronchial asthma.$12 -
Dosage form Tablets №20. Active ingredient 1 tablet contains ambroxol hydrochloride, calculated on 100 % basis – 30 mg. Indications Secretolytic therapy in acute and chronic diseases associated with disorders of bronchial secretions and loosening mucus advancement.$20 -
Dosage form Nail polish for medical use. Active ingredient amorolfine hydrochloride equivalent to amorolfine 50 mg. Indications Fungal lesions caused by dermatomycete, yeast fungus and mold, without affecting the nail base. Treatment of uncomplicated distal and lateral onychomycosis caused by dermatomycete, yeast fungus and mold fungus, delimited by two nails. Prevention of fungal nail infections.$45 -
DOSAGE FORM Tablets. ACTIVE INGREDIENT 1 tablet contains acetylsalicylic acid in terms of 100% of the substance – 500 mg. INDICATIONS Symptomatic treatment of headache, toothache, sore throat caused by cold; fever; algodysmenorrhea; pain in muscles and joints; back pain; moderate pain caused by arthritis. In case of cold or acute respiratory disease for symptomatic relief of pain and fever.$13 -
Dosage form Tablets №50. Active ingredient 1 tablet contains 40 mg of valerian extractum spissium, equivalent to dry substance. Indications Great nervous agitation, insomnia, in combined therapy of mild functional cardiovascular disturbances.$11 -
Dosage form Tablets №50. Active ingredient 1 tablet contains: valerian extractum spissium - 20 mg. Indications Great nervous agitation, insomnia, migraine, in combined therapy of mild functional cardiovascular and gastrointestinal disturbances.$11 -
Dosage form Tablets. Active ingredient 1 tablet contains bismuth nitrate basic, calculated on 282 mg of bismuth oxide – 350 mg, magnesium carbonate heavy, calculated on 168.5 mg of magnesium oxide – 400 mg, sodium hydrocarbonate – 200 mg, buckthorn bark powder – 25 mg, sweet flag root powder – 25 mg. Indications In the complex therapy of gastric ulcer and duodenal ulcer, functional dyspepsia, hyperacid gastritis.$11 -
DOSAGE FORM Film-coated tablets. Main physicochemical properties: film-coated tablets of white or almost white color, round shape, with a biconvex surface, odorless or with a slight odor of ammonia. COMPOSITION active ingredient : bismuth subcitrate; 1 tablet contains 320 mg of bismuth subcitrate, which is equivalent to 120 mg of bismuth oxide; excipients: corn starch, povidone, polacrilin potassium, magnesium stearate, coating mixture (polyethylene glycol, titanium dioxide (E 171), polyvinyl alcohol, talc). PHARMACOTHERAPEUTIC GROUP Drugs for the treatment of peptic ulcer and gastroesophageal reflux disease. Bismuth subcitrate ATX code A02B X05. INDICATIONS FOR USE Gastric and duodenal ulcers, chronic gastritis, including those caused by Helicobacter pylori (as part of anti-Helicobacter therapy regimens).$41 -
Dosage form Tablets №50. Active ingredient 1 tablet contains glycine recalculated to 100% substance 100 mg. Indications Functional and organic diseases of the nervous system (neurosis, neurosis states, vegetovascular dystonia, the effects neuroinfections, traumatic brain injury, perinatal and other forms of encephalopathy, including alcoholic genesis), accompanied by increased excitability, emotional instability, decreased mental capacity, sleep disorders. Ischemic stroke and cerebrovascular diseases. As an additional means in treatment of alcoholism.$15 -
DOSAGE FORM Solution for external application - fluid 50 ml. Active ingredient 1 vial contains 50 ml of dimethylsulfoxide. Indications Dimexid® is used for the treatment of inflammatory diseases of the musculoskeletal system (rheumatoid arthritis, Bechterew’s disease, deforming osteoarthritis, arthropathy, ligament sprain), contusions/bruises, traumatic infiltrates, inflammatory edemas, purulent wounds, abscesses, acute and chronic osteomyelitis, nodal fever, streptococcal impetigo. Dimexid® can be used in combination with nonsteroid anti-inflammatory drugs as combined therapy of deforming osteoarthrosis and rheumatoid arthritis, in combination with topical antimicrobial agents for the treatment of scleroderma, acne, erysipelatous inflammation, boils, eczema, trophic ulcers and other skin diseases, in combination with heparin – for the therapy of thrombophlebitis. Also used in skin-plastic surgery for preservation of skin allografts.$15 -
Dosage form Capsules №2. Active ingredient 1 capsule contains fluconazole, in terms of 100 % of the substance, 150 mg. Indications Vaginal candidiasis in patients who were previously diagnosed with (or appear sporadically) doctor.$12 -
Dosage form Tablets №10 or №30. Active ingredient 1 tablet contains drotaverinе hydrochloride 40 mg calculated as 100% substance. Indications Spasm of smooth muscles in visceral organs (cardio- and pyloric spasm), chronic gastroduodenitis, gastric and duodenal ulcers, cholelithiasis, nephrolithiasis (colics), chronic cholecystitis, postcholecystectomy syndrome, hypermotor biliary dyskinesia, spasmodic intestinal dyskinesia, intestinal colic associated with postoperative flatulence, colitis, proctitis, tenesmus, flatulence, pyelitis, headache associated with cerebral vasospasm, spasms of the coronary and peripheral arteries (obliterating endarteritis, Raynaud's disease), to weaken uterine contractions when needed and to relieve cervical spasm in labor, spasm of smooth muscles during instrumentation.$11 -
Dosage form Tablets №40. Active INGREDIENT 1 tablet contains dry extract of horse chestnut fruit 40 mg. Indications Chronic venous insufficiency of various origins and its complications (swelling, cramping calf muscles, pain and feeling of heaviness in the legs, varicose veins, trophic changes, hemorrhoids), postthrombophlebitis syndrome, inflammatory and postoperative swelling of soft tissues.$23 -
Dosage form Drops 25ml. Active ingredient 100 g of the preparation contains: horse chestnut (Aesculus hippocastanum) fruit liquid extract - 10.0 g, thiamine chloride - 0.5 g; list of excipients: ethyl alcohol, purified water. Indications Chronic lower limb venous insufficiency due to varicose disease and postthrombophlebitic syndrome. Inflammatory-edematous changes in functional circulatory disturbances of the lower limbs and rectum; phlebitis, edema, haemorrhoids.$14 -
Dosage form Tablets №10. Active ingredient 1 tablet contains 500 mg of calcium gluconate equivalent to 100% substance. Indications Diseases associated with hypocalcemia, increased cell membrane permeability, impaired transmission of nerve impulses in muscles. Hypoparathyroidism (latent tetany, osteoporosis), disturbances in vitamin D metabolism (rickets, spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal failure. High calcium requirements (the period of intensive growth in children and adolescents, pregnancy, lactation), nutritional Ca2+ deficiency, disorders of calcium metabolism in postmenopausal period, bone fractures. Intensive loss of Ca2 + (long-term bedridden patients, chronic diarrhea, hypocalcemia, long-term administration of diuretics, antiepileptic drugs, corticosteroids). As a part of combined therapy of bleedings of varying genesis, allergic diseases (serum sickness, rash, fever syndrome, pruritus, itching dermatoses, angioneurotic edema); bronchial asthma, hunger edema, pulmonary tuberculosis, eclampsia, parenchymatous hepatitis, toxic liver damage, nephritis. Poisoning with magnesium salt, oxalic acid, soluble salts of fluoric acid (binding to calcium gluconate results in forming insoluble and non-toxic calcium oxalate and calcium fluoride).$11 -
DOSAGE FORM Pills. Main physicochemical properties: Kasark®, tablets of 8 mg or 16 mg: tablets of white or almost white color, round shape, with a biconvex surface. Marbling is allowed on the surface of the tablet. Kasark®, 32 mg tablets: white or almost white, round tablets with a biconvex surface, with a score on one side of the tablet. Marbling on the surface of the tablet is allowed. COMPOSITION active ingredient : candesartan cilexetil; 1 tablet contains candesartan cilexetil, calculated as 100% substance, 8 mg or 16 mg, or 32 mg; excipients: carmellose calcium; corn starch; hydroxypropylcellulose; lactose monohydrate; magnesium stearate; polyethylene glycol (PEG 8000). PHARMACOTHERAPEUTIC GROUP Angiotensin II receptor antagonists. ATX code C09C A06. INDICATIONS FOR USE Treatment of essential hypertension in adults. Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction ≤ 40%) as add-on therapy to ACE inhibitors or in cases of intolerance to ACE inhibitors.$18 -
INDICATIONS FOR USE Delicate cleansing and moisturizing for dry, sensitive and atopy-prone skin of adults and children from birth. Moisturizes the skin for 48 hours. Promotes nourishment, softening of the skin and rapid skin recovery in the presence of combing; eliminates the feeling of tightness and discomfort caused by dryness; Gently exfoliates dead skin cells. How to use: apply KERASKIN cream with light massage movements at least 2 times a day (if necessary, you can use it more often). It can also be used in combination with products for restoring the skin's protective barrier - KERASKIN milk and facial and body skin cleansing - KERASKIN gel.$53 -
DOSAGE FORM Film-coated tablets. Main physicochemical properties: film-coated tablets, yellow in color, with a biconvex surface, with a score on one side of the tablet and embossing "KMP" on the other side. A white core is visible on the cross section. COMPOSITION active ingredient: clarithromycin; 1 tablet contains clarithromycin, calculated as 100% substance – 250 mg or 500 mg; excipients: microcrystalline cellulose; sodium starch glycolate (type A); sodium lauryl sulfate; hypromellose; calcium stearate; coating mixture "Opadry II Yellow" (contains: triacetin; hypromellose; lactose, monohydrate; titanium dioxide (E 171); polyethylene glycol; iron oxide yellow (E 172)). PHARMACOTHERAPEUTIC GROUP Antimicrobials for systemic use. Macrolides. ATX code J01F A09. INDICATIONS FOR USE • Treatment of infections caused by microorganisms susceptible to clarithromycin: • Upper respiratory tract infections, i.e. nasopharynx (tonsillitis, pharyngitis), and sinus infections. • Lower respiratory tract infections (bronchitis, acute lobar pneumonia and primary atypical pneumonia) (see sections “Pharmacological properties. • Pharmacodynamics” and “Special Instructions for Use” regarding susceptibility testing). • Skin and soft tissue infections (impetigo, folliculitis, erysipeloid, furunculosis, infected wounds) (see sections “Pharmacological properties. Pharmacodynamics” and “Special instructions for use” for susceptibility testing). • Acute and chronic odontogenic infections. • Disseminated or localized mycobacterial infections caused by Mycobacterium avium or Mycobacterium intracellulare. Localized infections caused by Mycobacterium chelonae, Mycobacterium fortuitum or Mycobacterium kansasii. • Eradication of H. pylori in patients with duodenal ulcer when suppressing hydrochloric acid secretion (clarithromycin activity against H. pylori at neutral pH is higher than at acidic pH).$14 -
Composition: active ingredients : perindopril, indapamide. 1 tablet contains: perindopril tertbutylamine - 4 mg (corresponding to 3.338 mg of perindopril) and indapamide - 1.25 mg; or perindopril tertbutylamine - 8 mg (corresponding to 6.676 mg of perindopril) and indapamide - 2.5 mg; Excipients: microcrystalline cellulose; lactose, monohydrate; colloidal anhydrous silicon dioxide; magnesium stearate. Dosage form: Tablets. Main physicochemical properties: 4 mg/1.25 mg tablets: white, oval tablets with a score on both sides and an embossed “+” image on each side of the score on one side of the tablet; 8 mg/2.5 mg tablets: white or almost white, round tablets with a score on one side. Pharmacotherapeutic group: Combinations of angiotensin-converting enzyme (ACE) inhibitors. Perindopril and diuretics. ATX code C09B A04. Indication. Treatment of essential hypertension.$16 -
COMPOSITION: active ingredients : perindopril, indapamide. 1 tablet contains: perindopril tertbutylamine - 4 mg (corresponding to 3.338 mg of perindopril) and indapamide - 1.25 mg; or perindopril tertbutylamine - 8 mg (corresponding to 6.676 mg of perindopril) and indapamide - 2.5 mg; Excipients: microcrystalline cellulose; lactose, monohydrate; colloidal anhydrous silicon dioxide; magnesium stearate. PHARMACEUTICAL FORM. Tablets. Main physicochemical properties: 4 mg/1.25 mg tablets: white, oval tablets with a score on both sides and an embossed “+” image on each side of the score on one side of the tablet; 8 mg/2.5 mg tablets: white or almost white, round tablets with a score on one side. PHARMACOTHERAPEUTIC GROUP: Combinations of angiotensin-converting enzyme (ACE) inhibitors. Perindopril and diuretics. ATX code C09B A04. INDICATION. Treatment of essential hypertension.$19 -
DOSAGE FORM Tablets №6 or №10. ACTIVE INGREDIENT 1 tablet contains acetylsalicylic acid* – 300 mg, paracetamol* – 100 mg, caffeine* – 50 mg. * equivalent to 100% of the substance INDICATIONS Mild or moderate pain syndrome (headache, arthralgia, migrane, toothache, neuralgia, primary dysmenorrhea). The drug can also be used as an antipyretic agent for diseases accompanied by fever.$11 -
Dosage form Lozenges. Active ingredient 1 lozenge contains Dequalinium Chloride calculated to 100 % substance 0.25 mg, Dibucaine hydrochloride calculated to 100 % substance 0.03 mg. Indications Local treatment of acute painful inflammatory infections of mouth and throat: gingivitis, ulcerative and aphtous stomatitis, tonsillitis, laryngitis and pharyngitis. LARYTYLEN also recommended for treatment of bad breath. LARYTYLEN could be used in cases of mixed infections of mouth and pharynx (under doctor`s prescription); as adjuvant treatment in angina catarrhalis, angina lacunaris and Paul-Vincent’s angina; candidiasis of mouth or throat. It is recommended in postsurgical period after tonsillectomy and dental extractions.$13 -
Dosage form Lozenges. Active ingredient 1 lozenge contains Dequalinium Chloride calculated to 100 % substance 0.25 mg, Dibucaine hydrochloride calculated to 100 % substance 0.03 mg. Indications Local treatment of acute painful inflammatory infections of mouth and throat: gingivitis, ulcerative and aphtous stomatitis, tonsillitis, laryngitis and pharyngitis. LARYTYLEN also recommended for treatment of bad breath. LARYTYLEN could be used in cases of mixed infections of mouth and pharynx (under doctor`s prescription); as adjuvant treatment in angina catarrhalis, angina lacunaris and Paul-Vincent’s angina; candidiasis of mouth or throat. It is recommended in postsurgical period after tonsillectomy and dental extractions.$13 -
Dosage form Lozenges. Active ingredient 1 lozenge contains Dequalinium Chloride calculated to 100 % substance 0.25 mg, Dibucaine hydrochloride calculated to 100 % substance 0.03 mg. Indications Local treatment of acute painful inflammatory infections of mouth and throat: gingivitis, ulcerative and aphtous stomatitis, tonsillitis, laryngitis and pharyngitis. LARYTYLEN also recommended for treatment of bad breath. LARYTYLEN could be used in cases of mixed infections of mouth and pharynx (under doctor`s prescription); as adjuvant treatment in angina catarrhalis, angina lacunaris and Paul-Vincent’s angina; candidiasis of mouth or throat. It is recommended in postsurgical period after tonsillectomy and dental extractions.$13 -
PHARMACEUTICAL FORM Powder for oral solution. Main physicochemical properties: white or almost white powder. COMPOSITION active ingredient: macrogol; 1 sachet contains polyethylene glycol (macrogol) 4000 in terms of 100% substance 4 g or 10 g. 1 can contains polyethylene glycol (macrogol) 4000 in terms of 100% substance 150 g or 300 g. PHARMACOTHERAPEUTIC GROUP Laxatives. Osmotic laxatives. Macrogol. ATX code A06A D15. INDICATIONS FOR USE Symptomatic treatment of constipation.$12 -
Combined drug for local use. The drug has a pronounced antibacterial, anti-inflammatory, anti-allergic and antiexudative action.$20